Multicenter studies incorporating serial sampling, harmonized assays, longer follow-up, and multivariable adjustment are needed to define how KIM-1 and FGF23 can be combined with clinical data to improve AKI detection, risk stratification, and outcome prediction. Here, FGF23 is linked to acute kidney injury.